Novartis announces technology platform collaboration with Cerulean Pharma

Novartis has agreed a new strategic collaboration with Cerulean Pharma to develop cutting-edge therapies based on novel technology.

The companies will work together to create nanoparticle-drug conjugate (NDC) product candidates, combining Cerulean's proprietary Dynamic Tumour Targeting technology with Novartis' proprietary compounds directed at up to five targets.

Dynamic Tumour Targeting allows for the creation of NDCs designed to selectively attack tumour cells, reduce toxicity by sparing the body's normal cells and enable therapeutic combinations.

Cerulean will create the product candidates, with Novartis taking responsibility for further development and commercialisation of any products resulting from the collaboration.

Under the terms of the deal, Cerulean will receive an upfront payment of $5 million (4.09 million pounds) plus funding for five full-time equivalents, as well as preclinical, clinical, regulatory and sales-based milestone fees for each target.

Christopher Guiffre, president and chief executive officer of Cerulean, said: "We are pleased to have the opportunity to contribute to Novartis' pipeline, and we believe that partnering with them will help accelerate our efforts to provide safer and more effective options to cancer patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.